Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 3 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, usual_care.

CSII + CGM

Core clinician-reference fields are available or not applicable.

Participants received 6 weeks of closed-loop therapy first.

Closed-loop therapy

The randomized, controlled, crossover, two-period, open-label, and multicenter study was conducted from August 2022 to July 2023 in 17 individuals (9 to receive 6 weeks of CSII + CGM first and 8 to receive 6 weeks of closed-loop therapy first).

Participants received 6 weeks of CSII + CGM first.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Closed-loop therapy enhances glycemic control in type 2 diabetes.

Not extracted from the authoritative source.

Clinician-reference record is usable with limitations in: sample_size, arms, comparator.

Hybrid closed-loop system improves glycemic control in neonatal diabetes.

Available source content was suppressed because validation identified a conflict.

Standard clinical practice

Participants received a hybrid follow-up program incorporating telemedicine consultations alongside face-to-face visits.

Hybrid Telemedicine Group

Participants assigned to the intervention arm had face-to-face visits at months 0, 6, and 12. Additionally, they had remote telemedicine consultations through the smartphone app at months 3 and 9.

Participants received conventional face-to-face follow-up care following standard clinical practice.

Participants were enrolled either in a hybrid follow-up program... or in conventional face-to-face follow-up care following a standard clinical practice.

Hybrid telemedicine improves glycemic control in type 1 diabetes

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 2 studies described adult participants.

1 of 2 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Structured population data were available for 3 of 3 supporting studies. 1 study described adult participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Upstream consistency scoring indicates mixed findings across the evidence.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

3 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 2 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved, usual_care.

Structured population data were available for 4 of 4 supporting studies. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: other, usual_care.

3 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 4 of 4 supporting studies. 4 studies described participants with type 2 diabetes. 4 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 3 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.

Evidence uses heterogeneous comparison contexts: placebo, unknown_unresolved, usual_care.

Structured population data were available for 6 of 6 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 3 studies described adult participants.

3 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, unknown_unresolved, usual_care.

3 of 6 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. 2 studies described participants with type 2 diabetes. 4 studies described adult participants.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, unknown_unresolved.

2 of 4 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 3 studies described adult participants.

4 of 4 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 7 of 7 supporting studies. Diabetes type was heterogeneous: 4 studies with type 2 diabetes, 1 studies with type 1 diabetes. 5 studies described adult participants.

3 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo, unknown_unresolved, usual_care.

2 studies contain conflicting p-value and significance fields; those significance claims are suppressed.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

Structured population data were available for 9 of 9 supporting studies. Diabetes type was heterogeneous: 4 studies with type 1 diabetes, 2 studies with type 2 diabetes. 7 studies described adult participants.

Hybrid closed-loop system × Glucose variability

Available supporting studies

Closed-loop therapy enhances glycemic control in type 2 diabetes.

Hybrid closed-loop system improves glycemic control in neonatal diabetes.

Hybrid telemedicine improves glycemic control in type 1 diabetes